Navigation Links
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to Reach USD 766 Mln by 2019, Says GBI Research in Its Report Available at

London, UK (PRWEB) January 06, 2014

Currently, esophageal and gastric cancers are the two major types of cancer associated with the gastrointestinal tract. These kinds of cancer are usually diagnosed only at advanced and incurable stages given a late onset of symptoms. However, the diseases also demonstrate low survival rates even in the early stages. At present, the key options used to treat esophageal and gastric cancers include surgery and chemotherapy. One monoclonal antibody (mAb), namely Herceptin, is currently marketed for the use in suitable patients with advanced gastro-esophageal or gastric junction cancer.

Nowadays, the late-stage esophageal and gastric cancers pipelines include numerous promising mAbs candidates that are likely to enter the marketplace during 2014-2019. Actual market environment is regarded as rather favourable for new mAbs, with weak impact from biosimilar exposure along with high pricing patterns. The value of the overall market for mAbs in gastric and esophageal cancers is expected to touch the USD 766 million mark by 2019.

In-demand research study "Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth" worked out by GBI Research has been recently published by Market Publishers Ltd.

Report Details:

Title: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Published: December, 2013
Pages: 106
Price:    US$ 3,500.00

The report is a comprehensive guide to the market for mAbs in gastric and esophageal cancers. It contains detailed diseases’ profiles, including coverage of symptoms, etiology, epidemiology, pathophysiology, risk factors, diagnosis, treatment options, etc.; highlights the historical and current development of the gastric and esophageal cancers overall pipelines, reviews the major pipeline products available, as well as uncovers vital data on the drugs that are expected to enter the market in the offing. The report traces the recent deals and strategic consolidations in the examined field, offers a profound analysis of pipeline drug clinical trials, draws up a forecast scenario of the market performance up to 2019, and also scrutinizes the impact of the expiry of key current patents on the current drugs, the emergence of new drugs, and certain changes in disease epidemiology across the main geographical markets – the US, Japan Canada, the UK, Germany, Italy, France, and Spain.

Report Features & Benefits:

  •     Determine and understand the unmet needs in the treatment of gastric and esophageal cancers.
  •     Evaluate the role of Herceptin and pinpoint the promising opportunities for other mAbs to enter the market.
  •     Get an idea of the pipeline scope and understand the prominent molecule types and mechanisms of action.
  •     Observe the trends prevailing in the field and at certain development phases.
  •     Assess the risks of the current and future programs for mAbs in gastric and esophageal cancers with the help of the clinical trial failure rate analysis.
  •     Trace the shift in clinical trial endpoints, and thus use the acquired knowledge to influence any future development programmes.
  •     Assess the key drivers and barriers of the market growth.
  •     Get an idea of how the market landscape is set to change through to 2019.

More insightful research reports by GBI Research can be found at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
2. Monoclonal antibody appears effective and safe in asthma Phase IIa trial
3. Monoclonal Antibodies Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
4. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at
5. Monoclonal antibody effective against norovirus
6. Global & China Monoclonal Antibody Market Analysis and 2017 Forecasts in New Research Report at
7. Maine Biotechnology Services-USDA-ARS Partnership Provides Monoclonal Antibodies to Aid in the Containment of Rift Valley Fever Virus
8. Global and China Monoclonal Antibody Industry Report 2013 Analysis and 2017 Market Focus by
9. Antibodies reverse type 1 diabetes in new immunotherapy study
10. Antibodies from rabbits reduce risks associated with
11. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: